Free Trial

Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume - Should You Buy?

Bavarian Nordic logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Bavarian Nordic saw unusually-strong trading volume Wednesday — about 2,847 shares traded, a 75% increase from the prior session, with the stock at $9.50 (previous close $9.3550).
  • Valuation and technicals: market capitalization is $2.26 billion with a P/E of 10.80 and beta 1.34, and the share price is trading below both its 50-day ($10.10) and 200-day ($10.68) moving averages.
  • Earnings and outlook: the company reported a quarterly loss of ($0.20) on $226.16 million revenue but showed a 22.2% net margin and 11.44% ROE, while analysts forecast full-year EPS of 0.67.
  • MarketBeat previews the top five stocks to own by May 1st.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 2,847 shares were traded during mid-day trading, an increase of 75% from the previous session's volume of 1,631 shares.The stock last traded at $9.50 and had previously closed at $9.3550.

Bavarian Nordic Stock Up 1.5%

The company has a market capitalization of $2.26 billion, a P/E ratio of 10.80 and a beta of 1.34. The business's 50-day moving average is $10.10 and its two-hundred day moving average is $10.68.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $226.16 million during the quarter. Bavarian Nordic had a return on equity of 11.44% and a net margin of 22.20%. Analysts predict that Bavarian Nordic will post 0.67 EPS for the current year.

About Bavarian Nordic

(Get Free Report)

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bavarian Nordic Right Now?

Before you consider Bavarian Nordic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic wasn't on the list.

While Bavarian Nordic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines